Effect of Self-Management Guidelines on Awareness and Self-Efficacy for Patients with Systemic Lupus Erythematosus

Mohammed, Shaymaa Elsayed Mosaad

doi:10.21608/pssjn.2018.33333

Effect of Self-Management Guidelines on Awareness and Self-Efficacy for Patients with Systemic Lupus Erythematosus

Author

Shaymaa Elsayed Mosaad Mohammed

Medical - Surgical Nursing, Faculty of Nursing - Port Said University

10.21608/pssjn.2018.33333

Abstract

Background: Systemic lupus erythematosus (SLE) is an autoimmune, rheumatic disease, potentially affecting most organ systems. The disease is commonly considered to be chronic and occurs in often unpredictable flares, with alternating low and high disease activity. Good self-management is essential to managing lupus; as individuals with SLE can improve their prognosis by learning about many aspects of the illness as well as closely monitoring their own health with their care providers. Aim of the study: This study aims to evaluate the effect of Self-Management Guidelines on Awareness, health outcome and Self-Efficacy for Patients with Systemic Lupus Erythematosus in Mansoura University Hospital. Study design: A quasi-experimental design was utilized to accomplish the aim of this study. Setting: The study was conducted at the medical department inpatients and medical clinics outpatients at Mansoura University Hospital. Subject: A convenient sample of all available patients admitted to the medical department inpatients and medical clinics outpatients at Mansoura University Hospital within 6 months which reached to 65 patients from September 2015 to February 2016. Tool of data collection: Health assessment Questionnaire, Self-Efficacy Scale and Lupus Awareness's Quiz. Results: there were high statistically significant difference regarding severe pain, generalized health status and level of awareness (P<0.001) post implementation of self-management guidelines. The study concluded that: The systemic Lupus Erythematosus self-management guidelines had positive effects on the patients in reducing disability, improving self-efficacy and patient awareness. The study recommended that: Further researches about self-management of patients with SLE are highly recommended to reach the peak level of health satisfaction among those patients

Keywords

References

Bellotti M. (2003): Systemic Lupus Erythematosus Quizes. Lancet. Feb 17; 369 (9561): 587-96.

Cerner Multum W., & Wolters T. (2011): Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. Sep 15; 61 (9): 1143-51.

De Groot F. (2013): Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 11:95-101.

Fries JF. (1978): Quality of life and Pharmacoleconomics in Clinical Trials, 2^nd ed, The Health Assessment Questionnaire- Status and Review. Philadelphia: Lippincott-Raven Pub, p227-237.

Giverson U. (2011): EULAR recommendations for the management of systemic lupus erythematosus. Report of a tasked of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Reum; 67(10):195-205.

Hakim L., Furnrohr R & Amann A. (2011): Under treatment of disease Activity in Systemic Lupus Erythematosus Patients with End stage Renal Failure is Associated with Increased All-cause Mortality. J Rheumatol. Nov; 38(11):2382-9.

Jerusalem, K., & Schwarzer, T. (1995): Self efficacy. In M. Gerrard & K. D McCaul (Eds), health behavior constructs: Theory, measurement and research. National Cancer Instituten. Available at: http://dccps.cancer.gov/brp/constructs/selfefficacy/index.html. Accessed in 11 June 2014.

Koehler F. (2011): Recommendations for adults patients with autoimmune inflammatory rheumatic disease, 2^nd ed, Mosby. Boston, Toronto. London, pp. 61-70.

Krupp L., LaRocca N., Muir-Nash J., & Steinberg A. (1989): The fatigue severity scale(FSS), Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 (10): 1121-1123. PubMed Abstract/Publisher full Text.

Long C. (2010): Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol. Nov-Dec; 25(6 Suppl 47): 107-13.

Lupus Foundation of America. (2012): Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken).64(6): 797-808.

Mendoza T., & Carrasco A. (2011): The lupus band test in systemic lupus erythematosus, 2^nd ed, Tronto, Saunders Comp.,p.p.100-20.

Merrill JT., Neuwelt CM., & Wallace DJ. (2010): Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1):222-33.

Myrthe J., Ottenhoff T., Dick U., & Rob de Jong. (2011): Prognosis, mortality and morbidity in systemic lupus erythematosus, 7^th ed. Philadelphia: Lippincott Williams & Wilkins; p.p. 1333-53.

Nicol T., & Warier M. (2011): Glucocorticoid in systemic lupus erythematosus. Clin Exp Rheumatol. Sep-oct 2011; 29(5 Suppl 68):S126-9.

Petterson S., Lovgren M., Eriksson LE. (2012): An exploration of patient-reported symptoms in Systemic lupus erythematosus and relationship to health-related quality of life. Scand J Rheumatol; 41:383-290.

Przegl Lek. (2008): Socio-economic evaluation among patients with chronic illness, Philadelphia: Lippincott Williams & Wilkins; p.p. 838-850.

Rahman A & Isenberg D. (2012): Systemic lupus erythematosus. N Eng J Med; 358: 929-939.

Ritterhouse L., Crowe S., & Niewold TB. (2011): Vitamin D deficiency is associated with an increased autoimmune response in health individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. Sep 2011; 70(9): 1569-74.

Sanz Y. (2010): Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. Feb 2010; 22(2Pt 1):181-7.

Sestak A., Furnrohr B., Harley J., & Namjou B. (2011): The genetics of systemic lupus erythematosusand implications for trargeted therapy. Ann Rheum Dis. Mar 2011; 70 Suppl l: i37-43.

Sohng T., Murdaca G., Colombo B., & Puppo F. (2011): Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmune Rev. Nov 2011; 11 (1):56-60.

Stanford Health Assessment Questionnaier. (2008): A review of its history, issues, progress & documentation. J Rheumatol, 30(1): 167-8.

Tsokos G. (2011): Systemic lupus erythematosus. N Engl J Med. Dec 2011; 365(22): 2110-21.

Watson R. (2011): Morbidity and mortality in systemic lupus erythematosus during a 10- year period. A comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore); 82:299-308.

Yariz Y., Qweeb W., & Etail T. (2012): Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis; 69: 1603-1.